Other situations where prophylactic treatment with vedolizumab could be suggested are (a) combination treatment with ipilimumab and a PD-1 inhibitor where the risk of severe enterocolitis is increased [3], and (b) adjuvant ICPI therapy in high-risk resected melanoma where the acceptance for irAEs may be decreased given an apparent lack of malignant disease [9]. The gene discussed is PDCD1; the disease is melanoma.